NattoPharma Signs Technology Licensing Agreement with ZümXR

Provides exclusive use of proprietary encapsulation technology for Vitamin K2

OSLO, NORWAY and METUCHEN, NJ (June 6, 2017) – NattoPharma has reached an accord with ZümXR that provides NattoPharma with the exclusive rights to add ZümXR’s proprietary, patented encapsulation technology to its Advance Delivery Platform™ (ADP) offering.

ADP enables NattoPharma customers to incorporate MenaQ7® in a broad range of delivery applications, which answers the growing consumer demand for innovative alternative delivery vehicles. This trend is evident in the expanding options for consumers to meet their nutritional needs beyond the traditional dietary supplement, be it with functional food or beverage products, gummies, or other multi-ingredient forms. 

A research company that specializes in novel, science-based, targeted-release and encapsulation services based in Denver, CO, USA, ZümXR’s background in the pharmaceutical industry equates to tighter product specifications, stringent quality standards, and an insistence upon delivering products based on science.

“ZümXR complements our existing water soluble and water dispersible delivery systems.  All are part of our ADP, which NattoPharma's R&D Solutions Division uses to meet our clients' needs,” says Eric Anderson, NattoPharma senior vice president of global sales and marketing. “Adding this technology to our ADP offering means we can better address an ever-expanding set of customer needs, and assures that we have the right product for our customers’ varied delivery systems.” 

“ZümXR is an excellent partner for NattoPharma,” adds Daniel Rosenbaum, NattoPharma CEO. “Like NattoPharma, science drives the innovations ZümXR puts on the market. It is this focus on clinical validation that caught our attention, and having the exclusive right to this proprietary technology adds to our  position as a global leader in the Vitamin K2 category.”

# # #

About NattoPharma and MenaQ7®

NattoPharma ASA, based in Norway, is the world’s leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, vitamin K2 as menaquinone-7 (MK-7) with guaranteed actives and stability, clinical substantiation, and

international patents granted and pending. The company has a multi-year research and development program to substantiate and discover the health benefits of vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPahrma USA, Inc., in Metuchen, NJ, and NattoPharma R&D Ltd. in Cyprus. For more information, visit or

About ZümXR®

Using a patented delivery system, ZümXR® develops and sells science-backed targeted-release ingredients and also offers custom encapsulation services.  Their patented delivery system gives nutritional supplement and beverage brands the ability to control the release rate and stabilize a variety of ingredients, making current products deliver more usable nutrients and carry stronger label claims.  ZümXR’s background in the pharmaceutical industry equates to tighter product specifications, stringent quality standards and more science behind each product.  Current offerings include time-release caffeine versions suitable for both ready-to-drink (RTD) beverages and non-RTD (stick pack, gummies, gels) applications.  ZümXR’s patented technology is suitable for numerous other nutritional ingredients.  Please visit for more information.

For more information, please contact:

Kate Quackenbush, NattoPharma Director of Communications

Phone: 609-643-0749 x 220



About Us

NattoPharma, the world leader in Vitamin K2 Research and Development, has invested millions of dollars in in-vitro, in-vivo, and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market. After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7®, NattoPharma has consistently answered and met market needs through the development of new production technologies:• In 2012, the company introduced MenaQ7® Crystals, which represented an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.• In 2014, NattoPharma introduced the only all-trans nature-identical synthesized Vitamin K2, MenaQ7® PURE. Not only did the company succeed in changing the market with MenaQ7® PURE – offering a high-quality, competitively priced ingredient – but its efforts were rewarded with the NutrAward for Best Functional Ingredient at Natural Products West/engredea 2015. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma’s all-trans MK-7 products in healthy and diseased populations, for bone and cardiovascular health. NattoPharma continues to build its competitive advantage through focuson IPR and has patents both granted and pending related to relevant healthbenefits and market segments, creating extra value for its customers. And NattoPharma staff consists of professionals people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. By understanding and controlling the chemistry, NattoPharma provides the market all-trans MK-7 products, while our sales and marketing team has extensive knowledge of international market demands with which it supports our partners.


Documents & Links